These findings strongly support our hypothesis that SynCav1, in part, protects the hippocampus from AD-associated neuropathological changes via enhancing molecular signaling components linked to synaptic plasticity, neuronal activity, and neuroprotection (i.e., p-CaMKII, p-CREB). This evidence concerns the gene CAMK2G and Alzheimer disease.